AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18378859 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal rise
Number of subjects: 392
Study 18378859 — intervention group
Group type: COMPARATOR
Intervention: Ambulatory monitoring data
Number of subjects: 392
Study 16601520 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive screening with myocardial perfusion imaging
Number of subjects: 47
Study 16601520 — intervention group
Group type: EXPERIMENTAL
Intervention: Discussion of laboratory test results with providers
Number of subjects: 47
Study 16601520 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 47
Study 14752538 — intervention group
Group type: EXPERIMENTAL
Intervention: Buteyko Breathing Technique (BBT)
Number of subjects: 38
Study 14752538 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 38
Study 10877010 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (single oral dose)
Number of subjects: 17
Study 9191757 — intervention group
Group type: EXPERIMENTAL
Intervention: ADAS-Cog
Number of subjects: 1648
Study 9191757 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple regression model
Number of subjects: 1648
Study 8193735 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 75 mg o.d.
Number of subjects: 18000
Study 8193735 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic blood pressure targets < or = 90 mmHg, < or = 85 mmHg, < or = 80 mmHg
Number of subjects: 18000
Study 8193735 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine 5 mg o.d. as basic antihypertensive treatment
Number of subjects: 18000
Study 8193735 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18000
Study 3989697 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg tablet formulation
Number of subjects: 12
Study 3989697 — intervention group
Group type: EXPERIMENTAL
Intervention: syrup formulation
Number of subjects: 12
Study 3989697 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg tablet formulation with different inactive excipients
Number of subjects: 12
Study 31505232 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventional training based on self-directed learning to develop shared mental models
Number of subjects: 141
Study 31505232 — intervention group
Group type: COMPARATOR
Intervention: Conventional instructor led training
Number of subjects: 141
Study 29461870 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment A (PR2.3.1)
Number of subjects: 57
Study 28361824 — intervention group
Group type: EXPERIMENTAL
Intervention: Foxtail millet dosa
Number of subjects: 105
Study 28361824 — intervention group
Group type: COMPARATOR
Intervention: Rice dosa
Number of subjects: 105
Study 25630582 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical spot-on formulation containing 6.76% w/v fipronil + 50.48% w/v permethrin
Number of subjects: 16
Study 25630582 — intervention group
Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 16
Study 23087736 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% CHX
Number of subjects: 60
Study 23087736 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% CHX
Number of subjects: 60
Study 23087736 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 20333793 — intervention group
Group type: COMPARATOR
Intervention: Glucose
Number of subjects: 15
Study 20333793 — intervention group
Group type: EXPERIMENTAL
Intervention: 23 test foods
Number of subjects: 15
Study 18565817 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium therapy (L-seleno-methionine 2 x 100 microg/day for one year)
Number of subjects: 132
Study 18565817 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium therapy
Number of subjects: 132
Study 18565817 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 132
Study 15717211 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of sarizotan
Number of subjects: 10
Study 15717211 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 12760988 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (n = 32)
Number of subjects: 64
Study 12760988 — intervention group
Group type: COMPARATOR
Intervention: Saline (n = 32)
Number of subjects: 64
Study 10713870 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron 4 mg
Number of subjects: 134
Study 10713870 — intervention group
Group type: COMPARATOR
Intervention: droperidol 75 micrograms kg‐1
Number of subjects: 134
Study 8722064 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive therapy
Number of subjects: 1441
Study 8722064 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 1441
Study 3404814 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine HCl, 250 mg/kg infused over 30 minutes
Number of subjects: 26
Study 3404814 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon, 6 ng/kg/min infused over 30 minutes
Number of subjects: 26
Study 3404814 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin, 150 mg
Number of subjects: 26
Study 3404814 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen, 800 mg
Number of subjects: 26
Study 3404814 — intervention group
Group type: COMPARATOR
Intervention: Control (no cyclooxygenase inhibitors)
Number of subjects: 26
Study 3404814 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin, 150 mg before second infusion of arginine
Number of subjects: 26
Study 3404814 — intervention group
Group type: COMPARATOR
Intervention: Arginine infusion
Number of subjects: 26
Study 31228219 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple dietary advice
Number of subjects: 59
Study 31228219 — intervention group
Group type: COMPARATOR
Intervention: Denture care advice (Control)
Number of subjects: 59
Study 28931532 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet intervention
Number of subjects: 0
Study 28931532 — intervention group
Group type: COMPARATOR
Intervention: High-fat diet intervention
Number of subjects: 0
Study 25174863 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal mometasone
Number of subjects: 388
Study 25174863 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 388
Study 21812821 — intervention group
Group type: EXPERIMENTAL
Intervention: RT-WBV
Number of subjects: 32
Study 21812821 — intervention group
Group type: COMPARATOR
Intervention: RT
Number of subjects: 32
Study 21949643 — intervention group
Group type: EXPERIMENTAL
Intervention: Early antiretroviral therapy (ART)
Number of subjects: 816
Study 21949643 — intervention group
Group type: COMPARATOR
Intervention: Standard antiretroviral therapy (ART)
Number of subjects: 816
Study 18436905 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic reminders
Number of subjects: 1922
Study 18436905 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1922
Study 21310502 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave therapy (ESWT); 39 patients/44 feet, twice per week for 6 treatments
Number of subjects: 77
Study 21310502 — intervention group
Group type: COMPARATOR
Intervention: Hyperbaric oxygen therapy (HBOT); 38 patients/40 feet, daily for 20 treatments
Number of subjects: 77
Study 21310502 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood flow perfusion rates
Number of subjects: 77
Study 15606437 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine at 0.25 mg kg(‐1) twice daily for 18 months
Number of subjects: 343
Study 15606437 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocetirizine 0.125 mg kg(‐1) twice daily
Number of subjects: 343
Study 12017416 — intervention group
Group type: EXPERIMENTAL
Intervention: FreeStyle meter
Number of subjects: 0
Study 12017416 — intervention group
Group type: COMPARATOR
Intervention: Original meter
Number of subjects: 0
Study 9494686 — intervention group
Group type: EXPERIMENTAL
Intervention: Pheromone
Number of subjects: 38
Study 9494686 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 8109769 — intervention group
Group type: EXPERIMENTAL
Intervention: Supraclavicular paravascular approach (Group S; n = 20)
Number of subjects: 40
Study 8109769 — intervention group
Group type: COMPARATOR
Intervention: Axillary approach (Group A; n = 20)
Number of subjects: 40
Study 3391881 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin acistrate (EA) 400 mg tid
Number of subjects: 100
Study 3391881 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin base (EB) 500 mg tid
Number of subjects: 100
Study 12111127 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc-MIBI uptake in responders
Number of subjects: 37
Study 12111127 — intervention group
Group type: COMPARATOR
Intervention: 99mTc-MIBI uptake in non-responders
Number of subjects: 37
Study 12111127 — intervention group
Group type: EXPERIMENTAL
Intervention: Survival rate correlation with ER
Number of subjects: 37
Study 12111127 — intervention group
Group type: EXPERIMENTAL
Intervention: Survival rate correlation with DR
Number of subjects: 37
Study 12111127 — intervention group
Group type: EXPERIMENTAL
Intervention: Survival for patients with ER > 3
Number of subjects: 37
Study 12111127 — intervention group
Group type: COMPARATOR
Intervention: Survival for patients with ER < 3
Number of subjects: 37
Study 12111127 — intervention group
Group type: EXPERIMENTAL
Intervention: Survival for patients with DR > 3
Number of subjects: 37
Study 12111127 — intervention group
Group type: COMPARATOR
Intervention: Survival for patients with DR < 3
Number of subjects: 37
Study 12111127 — intervention group
Group type: EXPERIMENTAL
Intervention: Survival for patients with Pgp score +2
Number of subjects: 37
Study 12111127 — intervention group
Group type: COMPARATOR
Intervention: Survival for patients with Pgp score +1
Number of subjects: 37
Study 12111127 — intervention group
Group type: COMPARATOR
Intervention: Survival for patients with Pgp score -
Number of subjects: 37
Study 31371795 — intervention group
Group type: EXPERIMENTAL
Intervention: SQ-LNS-plus
Number of subjects: 750
Study 31371795 — intervention group
Group type: COMPARATOR
Intervention: SQ-LNS
Number of subjects: 750
Study 29625591 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral treatment (ART) with an age-appropriate stimulation program, updated at 3 monthly intervals through the first year of life.
Number of subjects: 0
Study 29625591 — intervention group
Group type: COMPARATOR
Intervention: HIV-exposed uninfected children (HEU) not having received the stimulatory intervention.
Number of subjects: 0
Study 26517283 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose (HD) factor VIII (200 IU kg‐1 day‐1)
Number of subjects: 31
Study 26517283 — intervention group
Group type: COMPARATOR
Intervention: Low-dose (LD) factor VIII (50 IU kg‐1 3× per week)
Number of subjects: 31
Study 26517283 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombin generation assay (TGA)
Number of subjects: 31
Study 26517283 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-FVIII <1.0 BU
Number of subjects: 31
Study 25288176 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 0
Study 22168137 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly TM-based feedback with goal setting
Number of subjects: 45
Study 22168137 — intervention group
Group type: COMPARATOR
Intervention: Weekly TM-based drinking assessments without feedback
Number of subjects: 45
Study 22168137 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study 19660970 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 26
Study 19660970 — intervention group
Group type: COMPARATOR
Intervention: Discontinuation of Hormone Replacement Therapy (HRT)
Number of subjects: 26
Study 18535251 — intervention group
Group type: EXPERIMENTAL
Intervention: Low magnitudes of torque applied to the knee (0 to 10 N.m varus/valgus, 0 to 5 N.m internal/external)
Number of subjects: 20
Study 16133153 — intervention group
Group type: EXPERIMENTAL
Intervention: Varus gonarthrosis group
Number of subjects: 75
Study 16133153 — intervention group
Group type: COMPARATOR
Intervention: Valgus gonarthrosis group
Number of subjects: 75
Study 12005463 — intervention group
Group type: EXPERIMENTAL
Intervention: Elemental formula (EF)
Number of subjects: 0
Study 12005463 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymeric immune‐enhancing formula (PIEF)
Number of subjects: 0
Study 12005463 — intervention group
Group type: COMPARATOR
Intervention: Dextrose (control)
Number of subjects: 0
Study 9927002 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen sodium (500 mg, 2 times a day for 48 h)
Number of subjects: 8
Study 9927002 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 8
Study 8678250 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited intentional normovolaemic haemodilution to a haematocrit of 34% (Group A)
Number of subjects: 30
Study 8678250 — intervention group
Group type: COMPARATOR
Intervention: No intentional normovolaemic haemodilution (Group B)
Number of subjects: 30
Study 2128590 — intervention group
Group type: EXPERIMENTAL
Intervention: Pall BB 22 15 filters
Number of subjects: 3
Study 2128590 — intervention group
Group type: COMPARATOR
Intervention: Changing anesthetic circuits after every patient
Number of subjects: 3
Study 342594 — intervention group
Group type: EXPERIMENTAL
Intervention: Naftidrofuryl (Praxilene) 300 mg per day
Number of subjects: 60
Study 342594 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 31818835 — intervention group
Group type: EXPERIMENTAL
Intervention: Customised Appropriateness Evaluation Protocol (AEP) for evaluating hospitalisations
Number of subjects: 1181
Study 31818835 — intervention group
Group type: EXPERIMENTAL
Intervention: Customised Appropriateness Evaluation Protocol (AEP) for evaluating duration of hospitalisations
Number of subjects: 1181
Study 31818835 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert evaluations using the customised AEP
Number of subjects: 1181
Study 28479852 — intervention group
Group type: EXPERIMENTAL
Intervention: DWP05195 (10-600 mg single dose; 100-400 mg once daily for 8 days)
Number of subjects: 10
Study 28479852 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 28479852 — intervention group
Group type: EXPERIMENTAL
Intervention: DWP05195 (multiple doses)
Number of subjects: 10
Study 28479852 — intervention group
Group type: EXPERIMENTAL
Intervention: DWP05195 (up to 600 mg single dose; 400 mg multiple dose)
Number of subjects: 10
Study 25919553 — intervention group
Group type: EXPERIMENTAL
Intervention: HFOV combined with pulmonary surfactant (PS)
Number of subjects: 122
Study 25919553 — intervention group
Group type: COMPARATOR
Intervention: HFOV alone
Number of subjects: 122
Study 23203754 — intervention group
Group type: EXPERIMENTAL
Intervention: Success-adapted computer intervention (CogmedRM)
Number of subjects: 20
Study 23203754 — intervention group
Group type: COMPARATOR
Intervention: Non-adaptive, active control condition
Number of subjects: 20
Study 20701549 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient fortification in breakfast maize-porridge for 52 school days
Number of subjects: 151
Study 20701549 — intervention group
Group type: COMPARATOR
Intervention: Placebo powder in breakfast maize-porridge for 52 school days
Number of subjects: 151
Study 19384179 — intervention group
Group type: EXPERIMENTAL
Intervention: De novo sirolimus-based therapy without calcineurin inhibitors
Number of subjects: 0
Study 19384179 — intervention group
Group type: COMPARATOR
Intervention: Initial use of a calcineurin inhibitor for 2 to 4 months followed by conversion to sirolimus
Number of subjects: 0
Study 19384179 — intervention group
Group type: EXPERIMENTAL
Intervention: Delaying the introduction of sirolimus
Number of subjects: 0
Study 19384179 — intervention group
Group type: EXPERIMENTAL
Intervention: Late withdrawal of steroids
Number of subjects: 0
Study 16924997 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA cream
Number of subjects: 18
Study 16924997 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 18
Study 14598251 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) with Photofrin 2 mg/kg body weight, administered intravenously 2 days before intraluminal photoactivation (wavelength, 630 nm; light dose, 180 J/cm²)
Number of subjects: 39
Study 14598251 — intervention group
Group type: COMPARATOR
Intervention: Stenting alone
Number of subjects: 39
Study 14598251 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT)
Number of subjects: 39
Study 10672082 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 8986544 — intervention group
Group type: EXPERIMENTAL
Intervention: Transmandibular implant (TMI) with a triple bar and cantilever extensions, provided with an overdenture
Number of subjects: 0
Study 8986544 — intervention group
Group type: COMPARATOR
Intervention: Intramobile cylinder implants (IMZ) connected by a Dolder bar, provided with an overdenture
Number of subjects: 0
Study 8986544 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall complication scale
Number of subjects: 0
Study 1729935 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral transmucosal fentanyl citrate (OTFC) 15-20 micrograms/kg lozenge 45 min preoperatively and placebo intravenously after induction
Number of subjects: 100
Study 1729935 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral transmucosal fentanyl citrate (OTFC) 15-20 micrograms/kg lozenge 45 min preoperatively and droperidol 50 micrograms/kg intravenously after induction
Number of subjects: 100
Study 1729935 — intervention group
Group type: COMPARATOR
Intervention: Placebo lozenge 45 min preoperatively and placebo (normal saline) injected intravenously after induction
Number of subjects: 100
Study 1729935 — intervention group
Group type: COMPARATOR
Intervention: Placebo lozenge 45 min preoperatively and droperidol 50 micrograms/kg intravenously after induction
Number of subjects: 100
Study 6531960 — intervention group
Group type: EXPERIMENTAL
Intervention: Clone PXH107 (reassortant virus)
Number of subjects: 60
Study 6531960 — intervention group
Group type: EXPERIMENTAL
Intervention: Clone PX62 (non-reassortant virus)
Number of subjects: 60
Study 31510950 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to door to door solid waste collection service
Number of subjects: 413
Study 31510950 — intervention group
Group type: COMPARATOR
Intervention: Improper solid waste management practices
Number of subjects: 413
Study 29278428 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard medical therapy (SMT) plus G‐CSF 3 monthly plus GH daily (group A; n = 23)
Number of subjects: 65
Study 29278428 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard medical therapy (SMT) plus G‐CSF (group B; n = 21)
Number of subjects: 65
Study 29278428 — intervention group
Group type: COMPARATOR
Intervention: Standard medical therapy alone (group C; n = 21)
Number of subjects: 65
Study 26991619 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine infusion (initial bolus of 0.25 μg/kg and infusion of 0.25 μg/kg/min)
Number of subjects: 112
Study 26991619 — intervention group
Group type: EXPERIMENTAL
Intervention: Leg wrapping
Number of subjects: 112
Study 26991619 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 112
Study 24247587 — intervention group
Group type: EXPERIMENTAL
Intervention: MSCs
Number of subjects: 65
Study 24247587 — intervention group
Group type: EXPERIMENTAL
Intervention: BMCs
Number of subjects: 65
Study 24247587 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for MSCs)
Number of subjects: 65
Study 24247587 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for BMCs)
Number of subjects: 65
Study 22464501 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitraz odour
Number of subjects: 23
Study 22464501 — intervention group
Group type: COMPARATOR
Intervention: Organophosphate odour
Number of subjects: 23
Study 20346565 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioadhesive 0.2% CHX gel applied intraoperatively once after surgical removal of the third molar
Number of subjects: 38
Study 20346565 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel applied in an identical fashion
Number of subjects: 38
Study 20346565 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioadhesive 0.2% CHX gel
Number of subjects: 38
Study 20346565 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 38
Study 17634013 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentasaccharide (PS) long-term
Number of subjects: 146
Study 17634013 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentasaccharide (PS) short-term
Number of subjects: 146
Study 17634013 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated Heparin (UFH)
Number of subjects: 146
Study 17634013 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Molecular Weight Heparin (LMWH)
Number of subjects: 146
Study 16259543 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (6-12 mg/day) plus fluoxetine (25-50 mg/day) combination
Number of subjects: 500
Study 16259543 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine (6-12 mg/day)
Number of subjects: 500
Study 16259543 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine (25-50 mg/day)
Number of subjects: 500
Study 16259543 — intervention group
Group type: COMPARATOR
Intervention: Nortriptyline (25-175 mg/day)
Number of subjects: 500
Study 16259543 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine/fluoxetine combination
Number of subjects: 500
Study 16259543 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine/fluoxetine combination (subgroup analysis)
Number of subjects: 500
Study 12169040 — intervention group
Group type: EXPERIMENTAL
Intervention: Desloratadine 5mg
Number of subjects: 20
Study 12169040 — intervention group
Group type: EXPERIMENTAL
Intervention: Desloratadine 7.5mg
Number of subjects: 20
Study 12169040 — intervention group
Group type: EXPERIMENTAL
Intervention: Desloratadine 10mg
Number of subjects: 20
Study 12169040 — intervention group
Group type: EXPERIMENTAL
Intervention: Desloratadine 20mg
Number of subjects: 20
Study 9681726 — intervention group
Group type: EXPERIMENTAL
Intervention: s.c. rHuEpo
Number of subjects: 30
Study 9681726 — intervention group
Group type: COMPARATOR
Intervention: i.v. rHuEpo
Number of subjects: 30
Study 8018527 — intervention group
Group type: EXPERIMENTAL
Intervention: Formestane 250 mg
Number of subjects: 143
Study 8018527 — intervention group
Group type: EXPERIMENTAL
Intervention: Formestane 500 mg
Number of subjects: 143
Study 2572699 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam sedation
Number of subjects: 0
Study 2572699 — intervention group
Group type: COMPARATOR
Intervention: Standard psychomotor testing
Number of subjects: 0